Product
CEND-1/LSTA1
1 clinical trial
2 indications
Indication
Pancreatic Ductal AdenocarcinomaIndication
Pancreatic CancerClinical trial
A Randomised, Double-blinded Phase II Study of Gemcitabine and Nab-Paclitaxel With CEND-1/LSTA1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-10-01